EMA Authorised: Ranluspec (ranibizumab) — Lupin Europe GmbH

View source ↗

Summary

EMA authorised Ranluspec (ranibizumab) from Lupin Europe GmbH. The product is indicated for several retinal conditions including wet age-related macular degener…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• Ranluspec (ranibizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization. MAH: Lupin Europe GmbH. Decision date: 24/04/2026